how safe are glp-1 drugs Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity The GLP-1 revolution: What UAB
Description
7,33 Our analysis revealed that papilledema was significantly improved in the GLP-1 agonist group compared to the usual care group
E.BackxP
The leading hypothesis to reconcile these findings is the early worsening phenomenon, where rapid and substantial glycemic improvement temporarily exacerbates pre-existing DR
Medications targeting similar or additional incretin pathways come closest to replicating tirzepatide effects
